Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing (NCT07387263)
๐ฉบ Plain-English Summary (8th-Grade Level)
Genetic testing can alter therapy and surgical management for cancer patients and is therefore indicated as a first-line test for many newly diagnosed patients, including breast, ovarian, pancreatic, prostate and colon/GI patients. To reduce pressure on already constrained genetics clinics across Canada, some cancer centres are 'mainstreaming' genetic testing - whereby genetic testing is initiated and mediated by oncologists without traditional pre-test genetic counseling (GC) often using some form of paper-based patient pamphlets or videos. There is no standard, evidence-based approach to mainstreaming, leading to significant practice variation, a lack of coordinated care and ultimately, negative psychological impacts on patients. Digital solutions can address these gaps by providing a standardized, coordinated and patient-centered approach to deliver cancer genetic education. However, digital solutions for providing cancer genetics services are uncommon and clinical-effectiveness and service delivery outcomes have not been well-assessed. This study will test a digital mainstreaming platform called the Genetics Adviser for Mainstream care to assess its effectiveness in improving psychological outcomes and patient-centred care for mainstream cancer patients compared to standard of care.
Who can join: Review the eligibility criteria below.
Location: Sunnybrook Hospital โ Toronto, Ontario
Age range: 18 Years
๐งช Interventions in This Study
- Genetics Adviser for Mainstream Care (GA-Mainstream) (BEHAVIORAL)
- Mainstreaming Standard of Care (BEHAVIORAL)
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (2 Sites)
- Sunnybrook Hospital โ Toronto, Ontario
- Mount Sinai Hospital โ Toronto, Ontario
๐ Contact the Study Coordinator
Phone: (416) 864-6060
Email: marc.clausen@unityhealth.to
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cancer
- Ovarian Tissue Cryopreservation in Children โ Rochester, Minnesota
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study โ Aurora, Colorado
- Ex Onc SLED: A Study Utilizing A Weighted Sled for Horizontal Resistance Training โ Pittsburgh, Pennsylvania
- An Internet-based Program to Help Cancer Survivors Manage Pain โ Fort Smith, Arkansas
- Identification of Patients With Age-Related Clonal Hematopoiesis (ARCH) Among Cancer Survivors โ Toronto, Ontario
- Researching the Effect of Aerobic Exercise on Cancer โ Los Angeles, California
Explore by condition: All Cancer clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.